2-{2-[2-(2-Amino-acetylamino)-acetylamino]-3-phenyl-propionylamino}-4-methyl-pentanoic acid | 60254-83-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-{2-[2-(2-Amino-acetylamino)-acetylamino]-3-phenyl-propionylamino}-4-methyl-pentanoic acid
• 英文别名: 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate
• CAS: 60254-83-3
• 化学式: C₁₉H₂₈N₄O₅
• 分子量: 392.455
• InChiKey: OCMQTALHBUOBFN-UHFFFAOYSA-N

物化性质

• 沸点：
  784.6±60.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  151
• 氢给体数：
  5
• 氢受体数：
  6

安全信息

• 海关编码：
  2924299090

制备方法与用途

多肽(DES-TYR1)-LEU-ENKEPHALIN属于脑啡肽的片段，序列中包含4个氨基酸，具有较小的极性。

参考质量标准如下：

• 外观：白色粉末
• 纯度（HPLC）≥98.0%
• 醋酸根含量≤12.0%
• 水分含量≤8.0%
• 肽含量≥80.0%
• 内毒素≤50EU/mg
• 氨基酸组成分析≤±10%

文献信息

• DRUG DELIVERY AGENTS INCORPORATING MITOMYCIN
  申请人：Commission of the European Communities

  公开号：EP0804246A1

  公开（公告）日：1997-11-05
• Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
  申请人：Presnell C. Sharon

  公开号：US20060122104A1

  公开（公告）日：2006-06-08

  This invention relates, e.g., to a method for expanding mammalian acinar cells, comprising culturing the cells in a cell culture system comprising a cell culture medium and a cell attachment surface, under conditions wherein the acinar cells undergo a 3-4 fold expansion together with transdifferentiation into a modified cell phenotype (IP cells) showing characteristics of acinar cells and liver cells. The invention also relates to a method for transforming these IP cells to insulin-producing cells in vitro, comprising culturing the cells in a novel, defined medium. Also disclosed are suitable culture media for performing these methods, isolated cells having the phenotype of IP cells and/or produced by these methods, and kits for performing the methods.
• [EN] DRUG DELIVERY AGENTS INCORPORATING MITOMYCIN<br/>[FR] AGENTS D'ADMINISTRATION DE MEDICAMENTS COMPRENANT DE LA MITOMYCINE
  申请人：EUROPEAN COMMUNITY

  公开号：WO1995005200A1

  公开（公告）日：1995-02-23

  (EN) A conjugate of a carrier polymer and aziridine ring containing mitomycin (MMC) drug molecules is prepared by coupling the MMC molecules via their aziridine imino groups to spacer groups that terminate in protected amino groups, deprotecting said amino groups, recovering and purifying the spacer-MMC derivatives, and then coupling these derivatives via said deprotected terminal amino groups to the carrier polymer. Alternatively, the MMC may first be treated with an activating agent, e.g. carbodiimidazole, to form on activated MMC derivative which is then coupled directly to spacer groups linked to the carrier polymer.(FR) On prépare un conjugué d'un polymère excipient et d'un cycle d'aziridine contenant des molécules médicamenteuses de mytomycine (MMC) en couplant les molécules MMC par l'intermédiaire de leurs groupes imino aziridine à des groupes espaceurs qui se terminent en groupes amino protégés, déprotégeant ces groupes amino, en récupérant et purifiant les dérivés des groupes espaceurs-MMC, et enfin en couplant ces dérivés par l'intermédiaire de ces groupes amino terminaux déprotégés au polymère excipient. Dans une autre variante, les molécules MMC peuvent d'abord être traitées avec un agent d'activation, par exemple le carbodiimidazole, afin de se former sur le dérivé activé de MMC qui est ensuite couplé directement aux groupes espaceurs liés au polymère excipient.